Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 09:00 ET | Source: Heald

Heald Partners with Thatch Marketplace to Bring First-of-its-Kind Diabetes Reversal Program to Employees

ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Heald, a leader in digital-first diabetes reversal, today announced a new partnership with Thatch, the modern health benefits platform. Through...
April 23, 2026 07:00 ET | Source: Antag Therapeutics

Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will...
April 23, 2026 04:30 ET | Source: Custom Market Insights

Global Automated Insulin Delivery System Market Size/Share Worth USD 2684 Million by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Austin, TX, USA, April 23, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Automated Insulin Delivery System Market Size, Trends and Insights By Product...
April 22, 2026 09:00 ET | Source: EmblemHealth

EmblemHealth Expands Community Diabetes Wellness Program, Bringing Free, Citywide Support to New Yorkers

EmblemHealth, one of the nation’s largest not-for-profit health plans, today announced the citywide expansion of its Community Diabetes Wellness Program.
April 21, 2026 10:30 ET | Source: GLP Diet

GLP Diet App Launches Personalized Wellness App for GLP-1 Medication Users, Earns 2,500+ App Reviews

GLP Diet App supports GLP-1 users (Ozempic, Mounjaro) with meal plans, 5-min workouts & progress tracking. 2,700+ reviews.
April 20, 2026 07:37 ET | Source: NewcelX Ltd.

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived...
April 17, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...
April 07, 2026 07:09 ET | Source: Pluristyx, Inc.

Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology

Pluristyx announces a new U.S. patent for iACT Stealth™ technology, enabling "cloaking" of cells to treat autoimmune diseases without immune suppression.
March 27, 2026 10:36 ET | Source: Research and Markets

Clinical Nutrition for Diabetes Care Market Report 2026-2030 Featuring Profiles of Key Players - Pfizer, Bayer, Sanofi-Aventis, Abbott Labs, Roche and More

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Clinical Nutrition for Diabetes Care Market Report 2026" has been added to ResearchAndMarkets.com's offering. The clinical nutrition for diabetes...
March 26, 2026 19:36 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..